201. Galectin-3 causes enteric neuronal loss in mice after left sided permanent middle cerebral artery occlusion, a model of stroke.
- Author
-
Cheng X, Boza-Serrano A, Turesson MF, Deierborg T, Ekblad E, and Voss U
- Subjects
- AMP-Activated Protein Kinases metabolism, Animals, Colon innervation, Colon physiopathology, Disease Models, Animal, Ileum innervation, Ileum physiopathology, Infarction, Middle Cerebral Artery complications, Infarction, Middle Cerebral Artery physiopathology, MAP Kinase Kinase Kinases metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Stroke complications, Stroke etiology, Stroke physiopathology, Toll-Like Receptor 4 metabolism, Galectin 3 metabolism, Infarction, Middle Cerebral Artery metabolism, Microglia metabolism, Neurons physiology, Signal Transduction, Stroke metabolism
- Abstract
In addition to brain injury stroke patients often suffer gastrointestinal complications. Neuroimmune interactions involving galectin-3, released from microglia in the brain, mediates the post-stroke pro-inflammatory response. We investigated possible consequences of stroke on the enteric nervous system and the involvement of galectin-3. We show that permanent middle cerebral artery occlusion (pMCAO) induces loss of enteric neurons in ileum and colon in galectin-3(+/+), but not in galectin-3(-/-), mice. In vitro we show that serum from galectin-3(+/+), but not from galectin-3(-/-), mice subjected to pMCAO, caused loss of C57BL/6J myenteric neurons, while myenteric neurons derived from TLR4(-/-) mice were unaffected. Further purified galectin-3 (10(-6) M) caused loss of cultured C57BL/6J myenteric neurons. Inhibitors of transforming growth factor β-activated kinase 1 (TAK1) or AMP activated kinase (AMPK) counteracted both the purified galectin-3 and the galectin-3(+/+) pMCAO serum-induced loss in vitro. Combined we show that stroke (pMCAO) triggers central and peripheral galectin-3 release causing enteric neuronal loss through a TLR4 mediated mechanism involving TAK1 and AMPK. Galectin-3 is suggested a target for treatment of post-stroke complications.
- Published
- 2016
- Full Text
- View/download PDF